Granted Patent B2

US 12,514,956 · App. 17/538,762 · Granted Jan 6, 2026

Inventors: Michael P. Francis (Norfolk, VA); Kyle Christensen (Norfolk, VA)

Assignee: Embody, Inc.

A61L27/24A61L27/367B33Y10/00B33Y70/00B33Y80/00A61L2430/30

Abstract

Claims (13)

1 . A scaffold construct, comprising:

a plurality of substantially aligned collagen microfibers arranged in multiple layers, wherein the collagen microfibers are spaced on average between about 100 to about 1000 microns with respect to each other;

wherein a first portion of the collagen microfibers is coated by a first biocompatible solution comprising cells suspended in hyaluronic acid solution and a second portion of the collagen microfibers is coated by a second biocompatible solution different from the first biocompatible solution; and

wherein the first portion is disposed in a first longitudinal portion of the scaffold and the second portion is discretely disposed in a second longitudinal portion of the scaffold different from the first longitudinal portion.

2 . A scaffold construct, comprising:

a plurality of collagen microfibers fabricated on a rotating frame and arranged in a continuous loop configuration, wherein the microfibers are substantially parallel to one another and spaced on average between about 100 to about 1000 microns with respect to each other;

the collagen microfibers are coated with a first biocompatible solution and a second biocompatible solution, the first and second biocompatible solutions being different from each other; and

wherein the scaffold construct has mechanical properties approximating or exceeding those of human musculoskeletal tissues.

3 . A scaffold construct, comprising:

a plurality of collagen microfibers arranged in an organized configuration in a continuous loop,

wherein the microfibers are spaced on average between about 100 to about 1000 microns with respect to each other and have properties comparable to biological tissue;

wherein the collagen microfibers are coated with a first biocompatible hydrogel comprising fibrin gel and a second biocompatible hydrogel different from the first biocompatible hydrogel; and

wherein the first biocompatible hydrogel is formed by combining a first biocompatible solution with a second biocompatible solution during fabrication.

Assignments (1)

Continuity (3)

References Cited (73)